<DOC>
	<DOCNO>NCT02426918</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy 2 different dos intravenous oral Debio 1450 compare intravenous vancomycin oral linezolid treatment patient staphylococcal ABSSSI .</brief_summary>
	<brief_title>Study Debio 1450 Bacterial Skin Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Has clinically document infection skin skin structure suspect document caused staphylococcal pathogen Meets protocolspecified criterion qualification contraception Is willing able remain confine study unit entire duration treatment period comply restriction relate food , drink medication Voluntarily consent participate provide write informed consent prior protocolspecific procedure Has history current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Has sign , symptom history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff ; 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) ; 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>